Ozone Autohemotherapy for Health & Longevity - Quick Reference Sheet

Ozone Autohemotherapy for Health & Longevity

Created on 09/27/2026 – Quick Reference based on Evidence Review created using AI4L + evidence-mcp / GPT 6 – Audit

Ozone autohemotherapy is a procedure that treats blood outside the body with oxygen and ozone before intravenous reinfusion, studied for pain, fatigue, and impaired function. Benefits reported in people with illness do not establish longer life, disease prevention, or better performance in healthy adults. Serious blood-cell, circulation, and heart-rhythm events have been reported; their true frequency and the consequences of years of repeated treatment remain uncertain. (Full Review)

Protocol

Status of protocols
No validated longevity regimen
Research exposures are not an administration guide or established optimum.
Studied symptom course
10 sessions; 2–3 weekly
Fibromyalgia series: 100 mL blood + 100 mL gas at 25 μg/mL; uncontrolled.
Frequency and maintenance
Optimal schedule unestablished
Published schedules vary; no head-to-head evidence establishes lifelong maintenance for healthy adults.
Time to effect
Fatigue relief
3 weeks
Muscle-pain trial: changes also assessed at 6 months.
Visual function with age-related central vision loss
12 months
Assessed during a year-long treatment course.
Depressive symptoms accompanying pain and insomnia
3 weeks
Changes also assessed at 6 months.

Benefits

Contraindications
  • G6PD deficiency
  • Pregnancy, breastfeeding, and children
  • Active major bleeding, severe anemia, or clinically significant clotting abnormalities
  • Unstable cardiovascular disease or decompensated heart failure
  • Severe renal impairment or uncontrolled potassium elevation
  • Known severe allergy to required circuit materials or anticoagulants
  • Uncontrolled thyroid overactivity or iron overload
  • Previous heparin-induced thrombocytopenia: heparin-containing circuits
Key Interactions
  • Prescription anticoagulants (warfarin, apixaban, rivaroxaban)
  • Antiplatelet drugs (medicines reducing platelet clumping) (clopidogrel, aspirin); ibuprofen, naproxen
  • Heparin or citrate: citrate, particularly larger exposures
  • High-dose intravenous vitamin C
  • Antioxidant supplements (high-dose vitamin C, vitamin E, N-acetylcysteine; uncertain efficacy interaction)
  • Supplements affecting bleeding (concentrated ginkgo, high-dose vitamin E)
  • Other oxidative or extracorporeal treatments (ultraviolet blood treatment, high-pressure multipass ozone, blood filtration)
  • Cancer treatment (chemotherapy, radiotherapy)

Risk & Side Effects

  • High: Respiratory injury from accidental inhalation; Transient dizziness, nausea, and local discomfort
  • Medium: Blood-borne infection from unsafe handling
  • Low: Oxidative blood-cell injury and impaired oxygen carriage; Dangerous potassium elevation and rhythm disturbance; Gas embolism and neurological injury; Coronary spasm or thrombosis; Bleeding and anticoagulation complications; Material allergy and reinfusion reactions
  • Speculative: Cumulative harm from repeated oxidative exposure; Displacement of effective prevention or treatment

Monitoring

Marker Target Why
G6PD activityAssay normal range; no ozone-specific optimumG6PD: glucose-6-phosphate dehydrogenase, an enzyme protecting red cells; baseline activity test
Hemoglobin and blood-cell countsBaseline and age/sex laboratory ranges; no established functional targetAnemia and bleeding risk
Creatinine and estimated kidney filtrationStable individual baseline; no established ozone targetKidney injury
PotassiumUsual clinical interval ≈3.5–5.0 mmol/L; local range governs; no ozone-specific optimumRhythm risk
Bilirubin, lactate dehydrogenase, haptoglobinBaseline and changes; no ozone-specific targetSuspected red-cell breakdown
Clotting testsTreatment-specific if anticoagulated; no ozone-specific optimumBleeding context; selected by drugs, liver disease and circuit anticoagulant
Blood pressure and pulseResting baseline and session changes; no ozone-specific optimumInfusion tolerance
Disease-specific functionPredefined meaningful baseline change; no universal ozone targetClinical benefit; same validated instrument or task

Cadence: Proposed, not validated: baseline; symptoms/vital signs each session; blood count, kidney function and potassium after 1–2 sessions and at completion, earlier if symptoms arise. Function: 3–5 weeks and 1–3 months after stopping; red-cell breakdown tests symptom-triggered.

Qualitative Assessment

  • Function: Walking, work, symptom-limited activities. Sleep and energy: Repeated records under stable routines. Pain and cognition: Meaningful daily changes. Tolerability: Bruising, dizziness, breathlessness, palpitations, urine changes, recovery time.